Postmenopausal Bleeding with an Adnexal Mass and Rising CA-125
A 61-year-old G1P1 presents with two episodes of postmenopausal bleeding over 6 weeks and vague pelvic pressure. She is 9 years postmenopausal and has never used hormone therapy. She has no personal or family history of breast, ovarian, or colorectal cancer. Examination: BMI 27, no ascites, a mobile, nontender mass is palpable in the right adnexa approximately 8 cm, and the uterus is small and anteverted. Transvaginal ultrasound shows a complex right adnexal mass with solid components and septations, and an endometrial thickness of 9 mm. CA-125 is 145 U/mL. CBC and chemistry are normal.
1. What is your differential and initial workup, and how do you prioritize the endometrial finding?
Read the worked answer
The differential includes an ovarian neoplasm (epithelial ovarian cancer, borderline tumor, or less likely a germ cell or sex cord-stromal tumor), a metastatic lesion, or a benign complex cyst. The postmenopausal bleeding with a 9 mm endometrial stripe is a separate and important finding - it raises concern for endometrial hyperplasia or carcinoma, which can coexist with an ovarian tumor (e.g., endometrioid ovarian cancer with synchronous endometrial cancer).
Workup:
- Endometrial sampling with Pipelle or hysteroscopy/D&C to evaluate the 9 mm stripe and the bleeding. This should not be deferred.
- Pelvic ultrasound is done; next, cross-sectional imaging with CT or MRI of the abdomen and pelvis to characterize the mass and assess for metastatic spread.
- CA-125 is elevated but nonspecific; use it as a baseline and trend, not as a diagnostic test.
- Consider referral to gynecologic oncology.
Prioritization: the endometrial finding is a distinct cancer risk and requires tissue diagnosis. The adnexal mass needs surgical evaluation. Both should be addressed, and if surgery is planned, the endometrial biopsy result will guide whether a hysterectomy is part of the procedure.
2. Endometrial biopsy shows complex atypical hyperplasia; the adnexal mass is suspicious for malignancy. What is your surgical plan, and what determines the extent of staging?
Read the worked answer
Given atypical hyperplasia and a suspicious adnexal mass, the appropriate surgery is exploratory laparotomy with staging for ovarian cancer, including total hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and pelvic and para-aortic lymph node assessment, plus peritoneal washings and biopsies of suspicious areas. The final extent depends on intraoperative findings and frozen section.
Reasoning: if the ovarian mass is malignant, she needs full staging. If frozen section shows a benign or borderline ovarian tumor, the staging can be modified. The atypical hyperplasia is treated definitively by hysterectomy, which is already part of the plan. If the ovarian tumor is an endometrioid carcinoma, synchronous endometrial cancer should be considered, and the endometrial pathology is already known.
Intraoperative decision-making: if there is gross metastatic disease, complete cytoreduction is the goal. If the tumor appears confined, staging lymphadenectomy or sentinel lymph node biopsy (if available and appropriate) guides adjuvant therapy. The prior atypical hyperplasia does not change the ovarian staging approach.
3. Final pathology shows stage IC1 endometrioid ovarian carcinoma and stage IA grade 1 endometrial carcinoma. How do you counsel her about adjuvant therapy and prognosis?
Read the worked answer
She has two primary cancers: stage IC1 (capsule rupture or surface involvement, depending on the exact substage) endometrioid ovarian carcinoma and stage IA grade 1 endometrial carcinoma. Both are low-grade endometrioid histology, which is favorable.
Adjuvant therapy: for stage IC1 grade 1 endometrioid ovarian cancer, adjuvant platinum-based chemotherapy (carboplatin plus paclitaxel) is generally recommended, typically 3–6 cycles, because stage IC disease carries a meaningful recurrence risk. The endometrial cancer is stage IA grade 1 with no adverse features and does not require adjuvant treatment; it is managed by the hysterectomy she has already had.
Prognosis: both are early-stage, low-grade tumors with generally favorable outcomes, but she needs surveillance - physical exam, CA-125 if it was elevated, and imaging as clinically indicated. She should be counseled about the possibility of recurrence, the role of genetic testing (endometrioid ovarian cancer can be associated with Lynch syndrome), and the importance of follow-up. Her overall prognosis is good, but the ovarian cancer drives the adjuvant plan.